Is SGMT or KALA more profitable?

Sagimet Biosciences' return on equity of -37.57% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Sagimet Biosciences N/A -37.57% -35.52% KALA BIO N/A -1,336.10% -94.85%

Do analysts rate CNTN or KALA?

KALA BIO has a consensus target price of $1,018.75, indicating a potential upside of 60,539.88%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts clearly believe KALA BIO is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, CNTN or KALA?

Hillstream Biopharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is CNTN or KALA more profitable?

Hillstream Biopharma's return on equity of -31.50% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% KALA BIO N/A -1,336.10% -94.85%

Is KALA or CHRS more profitable?

Coherus Oncology has a net margin of 397.30% compared to KALA BIO's net margin of 0.00%. Coherus Oncology's return on equity of -198.90% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% Coherus Oncology 397.30% -198.90% -46.65%

Which has stronger valuation and earnings, KALA or TARA?

Protara Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$96.14 N/A Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A

Is KALA or TARA more profitable?

Protara Therapeutics' return on equity of -38.70% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% Protara Therapeutics N/A -38.70% -36.02%

KALA BIO (KALA) Competitors

$1.68 -0.10 (-5.62%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.76 +0.08 (+4.46%)

As of 07/2/2026 07:58 PM Eastern

Compare

KALA vs. SGMT, CNTN, CHRS, TARA, and VYGR

Should you buy KALA BIO stock or one of its competitors? MarketBeat compares KALA BIO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with KALA BIO include Sagimet Biosciences (SGMT), Hillstream Biopharma (CNTN), Coherus Oncology (CHRS), Protara Therapeutics (TARA), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry.

How does KALA BIO compare to Sagimet Biosciences?

Sagimet Biosciences (NASDAQ:SGMT) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Sagimet Biosciences has a beta of 3.35, meaning that its stock price is 235% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, meaning that its stock price is 335% less volatile than the broader market.

In the previous week, Sagimet Biosciences had 1 more articles in the media than KALA BIO. MarketBeat recorded 1 mentions for Sagimet Biosciences and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.87 beat Sagimet Biosciences' score of 0.94 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Overall Sentiment
Sagimet Biosciences	Positive
KALA BIO	Very Positive

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by insiders. Comparatively, 2.2% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sagimet Biosciences' return on equity of -37.57% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
KALA BIO	N/A	-1,336.10%	-94.85%

Sagimet Biosciences presently has a consensus target price of $25.57, indicating a potential upside of 236.02%. KALA BIO has a consensus target price of $1,018.75, indicating a potential upside of 60,539.88%. Given KALA BIO's higher possible upside, analysts plainly believe KALA BIO is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

KALA BIO has lower revenue, but higher earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	123.97	-$51.04M	-$1.34	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

Summary

Sagimet Biosciences beats KALA BIO on 10 of the 14 factors compared between the two stocks.

How does KALA BIO compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and KALA BIO (NASDAQ:KALA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

In the previous week, Hillstream Biopharma had 1 more articles in the media than KALA BIO. MarketBeat recorded 1 mentions for Hillstream Biopharma and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.87 beat Hillstream Biopharma's score of 0.00 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Overall Sentiment
Hillstream Biopharma	Neutral
KALA BIO	Very Positive

KALA BIO has a consensus target price of $1,018.75, indicating a potential upside of 60,539.88%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts clearly believe KALA BIO is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Hillstream Biopharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by insiders. Comparatively, 2.2% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Hillstream Biopharma's return on equity of -31.50% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
KALA BIO	N/A	-1,336.10%	-94.85%

Hillstream Biopharma has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market.

Summary

KALA BIO beats Hillstream Biopharma on 7 of the 13 factors compared between the two stocks.

How does KALA BIO compare to Coherus Oncology?

KALA BIO (NASDAQ:KALA) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Coherus Oncology has higher revenue and earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
Coherus Oncology	$42.17M	5.30	$168.02M	$1.67	0.87

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by company insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Coherus Oncology has a net margin of 397.30% compared to KALA BIO's net margin of 0.00%. Coherus Oncology's return on equity of -198.90% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
Coherus Oncology	397.30%	-198.90%	-46.65%

KALA BIO presently has a consensus price target of $1,018.75, suggesting a potential upside of 60,539.88%. Coherus Oncology has a consensus price target of $8.67, suggesting a potential upside of 497.70%. Given KALA BIO's higher probable upside, equities analysts plainly believe KALA BIO is more favorable than Coherus Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

KALA BIO has a beta of -2.35, meaning that its stock price is 335% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

In the previous week, Coherus Oncology's average media sentiment score of 1.89 beat KALA BIO's score of 1.87 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
KALA BIO	Very Positive
Coherus Oncology	Very Positive

Summary

Coherus Oncology beats KALA BIO on 13 of the 14 factors compared between the two stocks.

How does KALA BIO compare to Protara Therapeutics?

KALA BIO (NASDAQ:KALA) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 2.2% of KALA BIO shares are held by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

KALA BIO currently has a consensus target price of $1,018.75, suggesting a potential upside of 60,539.88%. Protara Therapeutics has a consensus target price of $26.25, suggesting a potential upside of 546.55%. Given KALA BIO's higher probable upside, equities analysts plainly believe KALA BIO is more favorable than Protara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Protara Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

Protara Therapeutics' return on equity of -38.70% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
Protara Therapeutics	N/A	-38.70%	-36.02%

KALA BIO has a beta of -2.35, meaning that its share price is 335% less volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

In the previous week, Protara Therapeutics had 3 more articles in the media than KALA BIO. MarketBeat recorded 3 mentions for Protara Therapeutics and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.87 beat Protara Therapeutics' score of 0.47 indicating that KALA BIO is being referred to more favorably in the media.

Company	Overall Sentiment
KALA BIO	Very Positive
Protara Therapeutics	Neutral

Summary

Protara Therapeutics beats KALA BIO on 9 of the 13 factors compared between the two stocks.

How does KALA BIO compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

In the previous week, Voyager Therapeutics had 4 more articles in the media than KALA BIO. MarketBeat recorded 4 mentions for Voyager Therapeutics and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.87 beat Voyager Therapeutics' score of 0.79 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Overall Sentiment
Voyager Therapeutics	Positive
KALA BIO	Very Positive

KALA BIO has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	5.66	-$119.72M	-$1.97	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Voyager Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 336.51%. KALA BIO has a consensus price target of $1,018.75, indicating a potential upside of 60,539.88%. Given KALA BIO's higher possible upside, analysts plainly believe KALA BIO is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

KALA BIO has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
KALA BIO	N/A	-1,336.10%	-94.85%

Voyager Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, suggesting that its stock price is 335% less volatile than the broader market.

Summary

Voyager Therapeutics beats KALA BIO on 11 of the 16 factors compared between the two stocks.

Get KALA BIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KALA vs. The Competition

Export

Metric	KALA BIO	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$33.09M	$3.65B	$6.82B	$12.56B
Dividend Yield	N/A	2.22%	2.68%	6.63%
P/E Ratio	-0.02	21.43	27.92	24.56
Price / Sales	N/A	324.27	533.51	97.33
Price / Cash	N/A	143.20	48.59	58.15
Price / Book	0.13	8.66	10.91	6.45
Net Income	-$26.98M	$23.81M	$3.57B	$336.71M
7 Day Performance	-33.33%	3.47%	2.21%	1.37%
1 Month Performance	-25.00%	8.53%	4.58%	1.67%
1 Year Performance	-99.36%	62.64%	33.45%	24.05%

KALA BIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KALA KALA BIO	3.1522 of 5 stars	$1.68 -5.6%	$1,018.75 +60,539.9%	-99.3%	$33.09M	N/A	N/A	30	Positive News
SGMT Sagimet Biosciences	3.232 of 5 stars	$6.93 -1.8%	$25.57 +269.0%	-6.2%	$230.05M	$2M	N/A	8
CNTN Hillstream Biopharma	0.1256 of 5 stars	$2.66 -17.6%	N/A	N/A	$225.47M	N/A	N/A	2
CHRS Coherus Oncology	3.7066 of 5 stars	$1.52 +4.1%	$8.67 +470.2%	+82.4%	$225.21M	$42.17M	0.91	330	Positive News
TARA Protara Therapeutics	3.5012 of 5 stars	$4.03 +0.8%	$26.25 +551.4%	+46.0%	$224.82M	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KALA) was last updated on 7/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

KALA BIO (KALA) Competitors

KALA vs. SGMT, CNTN, CHRS, TARA, and VYGR

How does KALA BIO compare to Sagimet Biosciences?

Summary

How does KALA BIO compare to Hillstream Biopharma?

Summary

How does KALA BIO compare to Coherus Oncology?

Summary

How does KALA BIO compare to Protara Therapeutics?

Summary

How does KALA BIO compare to Voyager Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA vs. The Competition

KALA BIO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

KALA BIO (KALA) Competitors

KALA vs. SGMT, CNTN, CHRS, TARA, and VYGR

How does KALA BIO compare to Sagimet Biosciences?

Which has more volatility and risk, SGMT or KALA?

Does the media prefer SGMT or KALA?

Do institutionals & insiders believe in SGMT or KALA?

Is SGMT or KALA more profitable?

Do analysts prefer SGMT or KALA?

Which has preferable valuation and earnings, SGMT or KALA?

Summary

How does KALA BIO compare to Hillstream Biopharma?

Does the media refer more to CNTN or KALA?

Do analysts rate CNTN or KALA?

Which has stronger valuation & earnings, CNTN or KALA?

Do institutionals and insiders hold more shares of CNTN or KALA?

Is CNTN or KALA more profitable?

Which has more volatility and risk, CNTN or KALA?

Summary

How does KALA BIO compare to Coherus Oncology?

Which has stronger valuation & earnings, KALA or CHRS?

Do institutionals & insiders hold more shares of KALA or CHRS?

Is KALA or CHRS more profitable?

Do analysts prefer KALA or CHRS?

Which has more risk and volatility, KALA or CHRS?

Does the media refer more to KALA or CHRS?

Summary

How does KALA BIO compare to Protara Therapeutics?

Do institutionals and insiders have more ownership in KALA or TARA?

Do analysts recommend KALA or TARA?

Which has stronger valuation and earnings, KALA or TARA?

Is KALA or TARA more profitable?

Which has more volatility & risk, KALA or TARA?

Does the media favor KALA or TARA?

Summary

How does KALA BIO compare to Voyager Therapeutics?

Does the media prefer VYGR or KALA?

Which has preferable valuation & earnings, VYGR or KALA?

Do insiders and institutionals hold more shares of VYGR or KALA?

Do analysts recommend VYGR or KALA?

Is VYGR or KALA more profitable?

Which has more risk and volatility, VYGR or KALA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA vs. The Competition

KALA BIO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools